DualityBio-B (09606) rose more than 5% during intraday trading, and as of press time, was up 4.32% at HK$111.1, with a turnover of HK$144 million.
On the news front, on the evening of October 28, DualityBio announced that it had repurchased a total of 794,200 shares on the announcement date, at a total consideration of approximately HK$125 million. All repurchased shares are held as treasury shares.
Based on continued confidence in the group's future development prospects and recognition of the company's long-term investment value, in addition to the initial increase, founder, chairman, executive director, and chief executive officer Zhu Zhongyuan intends to further increase his shareholding through the purchase of shares in the open market with his own funds, with an additional total amount not exceeding US$5 million, and the total amount of the initial increase and the further increase is expected not to exceed US$10 million.
CMB International recently issued a research report stating that the company's valuation is still primarily driven by its B7-H3 ADC asset Elfe-D. The bank noted that Elfe-D is expected to become a blockbuster product, supported by emerging efficacy, differentiated safety, and potential first-mover advantages in ADC + IO 2.0 combinations; the latest ESMO update together with last month's WCLC data further strengthens this investment thesis, showing encouraging early efficacy across lung cancer and non-lung cancer solid tumors (including SCLC, PROC, HCC, and CC), with manageable tolerability.
Comments